June 2024 in “Indian Dermatology Online Journal” Topical tofacitinib is effective and safe for treating alopecia areata.
January 2021 in “Journal of Cancer Therapy” Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.
87 citations
,
March 2013 in “Expert Review of Anticancer Therapy” Afatinib often causes skin problems that need proactive management.
2 citations
,
March 2022 in “Modern Rheumatology Case Reports” A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.
February 2011 in “Annales de dermatologie et de vénéréologie” Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
3 citations
,
July 2025 in “International Immunopharmacology”
2 citations
,
April 2022 in “Cutaneous and Ocular Toxicology” Tofacitinib may help treat hair loss in children with alopecia areata.
139 citations
,
November 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
11 citations
,
November 2019 in “Clinical Case Reports” A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.
February 2019 in “Dermatologic Surgery” June 2025 in “British Journal of Dermatology” Tofacitinib was more effective than methotrexate for treating alopecia areata.
April 2018 in “Dermatologic Surgery”
2 citations
,
January 2020 in “Einstein (São Paulo)” Topical tofacitinib shows promise as a future treatment for alopecia areata.
3 citations
,
November 1998 in “PubMed”
March 2025 in “Indian Journal of Dermatology Venereology and Leprology” Tofacitinib is effective for treating alopecia totalis and universalis, with some patients experiencing significant hair regrowth.
February 2006 in “Inpharma Weekly” February 2007 in “Journal of Clinical Dermatology”
39 citations
,
January 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.
6 citations
,
August 2014 in “Toxicologic pathology” Blocking DGAT1 reduces oil gland size in mice and dogs, but only mice experience hair loss.
January 2025 in “International Journal of Dermatology Venereology and Leprosy Sciences” Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.
8 citations
,
February 2010 in “Journal of Dermatology” A topical treatment safely and effectively reduced acne by causing targeted cell death in sebaceous glands without side effects.
54 citations
,
September 2019 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.
October 2019 in “Asian College of Neuropsychopharmacology”
15 citations
,
December 2014 in “Dermatology and therapy” Sorafenib can cause facial acne-like eruptions, which improve after reducing the dose or stopping the drug.
10 citations
,
September 2016 in “Journal of cutaneous medicine and surgery” Patients on dabrafenib and trametinib for melanoma often experience skin side effects.
January 1999 in “Journal of the European Academy of Dermatology and Venereology” RAPK is a rare skin disorder with pigmented spots, mainly on hands and feet, starting in youth.
January 2025 in “Journal of Crohn s and Colitis” Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
5 citations
,
January 2021 in “Inflammatory Bowel Diseases” Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
49 citations
,
March 2017 in “Journal of the American Academy of Dermatology” Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
3 citations
,
August 2020 in “Case Reports in Dermatology” Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.